Rigel Pharmaceuticals Inc (RIGL)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $823.43M
Last updated: Nov 17, 2026 at 4:15 PM ET
Rigel Pharmaceuticals Inc (RIGL) Stock Chart
Rigel Pharmaceuticals (RIGL) has a latest price of $42.92 on Nov 17, 2026, 18.4% below its 52-week high of $52.60. Its price rose 2.3% over the past 12 months. The month-end price rose 97.3% over the 10 years through Oct 2026, a compound annual rate of 7.0%.
Price Chart
From Oct 2016 to Oct 2026, its highest month-end close was $51.31 in Oct 2026 and its lowest $6.72 in Nov 2022, adjusted for splits.
Month-end closes, adjusted for splits. Dividends are not included.
Chart RIGL with Advanced Charting
Daily candlesticks, valuation multiples, side-by-side comparisons and drawings for RIGL.
Free with a GNG account. No credit card.
Price Performance
Over the past 3 months the price fell 8.6%, and over 6 months it rose 51.7%. The month-end price rose 535.6% over the 3 years through Oct 2026, a compound annual rate of 85.2%.
| Period | Change |
|---|---|
| 1 month | -8.1% |
| 3 months | -8.6% |
| 6 months | +51.7% |
| 12 months | +2.3% |
| 12 months, with dividends | +2.3% |
| Period | Change | Per year |
|---|---|---|
| 3 years | +535.6% | +85.2% |
| 5 years | +52.7% | +8.8% |
| 10 years | +97.3% | +7.0% |
Price by Year
Its best calendar year was 2025, when the price rose 154.6%, and its weakest was 2022, when it fell 43.4%.
| Year | Close | Change |
|---|---|---|
| 2026 through Oct 2026 | $51.31 | +19.8% |
| 2025 | $42.83 | +154.6% |
| 2024 | $16.82 | +16.0% |
| 2023 | $14.50 | -3.3% |
| 2022 | $15.00 | -43.4% |
| 2021 | $26.50 | -24.3% |
| 2020 | $35.00 | +63.6% |
| 2019 | $21.40 | -7.0% |
| 2018 | $23.00 | -40.7% |
| 2017 | $38.80 | +63.0% |
Trading Range
The price is 9.2% below its 50-day average of $47.25 and 14.0% above its 200-day average of $37.66.
| Measure | Value | Price vs |
|---|---|---|
| Latest price (Nov 17, 2026) | $42.92 | |
| 52-week high | $52.60 | -18.4% |
| 52-week low | $24.95 | +72.0% |
| 50-day average | $47.25 | -9.2% |
| 200-day average | $37.66 | +14.0% |
Price Risk
Over 3 years, its largest fall from a peak was 50.8%.
| Measure | Value |
|---|---|
| 1-year beta | 1.08 |
| Largest fall, 1 year | -50.1% |
| Largest fall, 3 years | -50.8% |
Advanced Charting Features
Advanced Charting is free with a GNG account, and signed-in members get it in place of the price chart above.
- Valuation multiples. Daily P/E, price to sales, cash flow and book value, PEG and PEGY, drawn behind the price wherever the company's data supports them.
- Price charts and drawings. Candlestick, OHLC, line and area charts with volume and earnings, dividend and split markers, plus trend lines, levels and notes kept in your account.
- Side-by-side compare. Two stocks next to each other on one metric and time span, each chart with its own price scale.
- Projections and saved views. Pick a start and an end point to see the price return, dividends and total return between them, and save views to open later.
Frequently Asked Questions About RIGL
What is RIGL's 1-year price change?
Rigel Pharmaceuticals's price rose 2.3% over the past 12 months. With dividends included, the 12-month total return was 2.3%.
What is RIGL's 5-year price change?
Rigel Pharmaceuticals's month-end price rose 52.7% over the 5 years through Oct 2026, a compound annual rate of 8.8%. These figures leave out dividends.
What is RIGL's 52-week high and low?
Rigel Pharmaceuticals's 52-week high is $52.60 and its 52-week low is $24.95. Its latest price of $42.92 on Nov 17, 2026 is 18.4% below the high.
What is RIGL's beta?
Rigel Pharmaceuticals's 1-year beta against the S&P 500 is 1.08, so its price has moved about in line with the market over the past year. Its largest fall from a peak over the past year was 50.1%.
Is the RIGL chart free?
Yes. Advanced Charting for RIGL is free with a GNG account, and no credit card is needed. It adds daily candlestick and line charts with volume, valuation multiples, side-by-side comparisons, drawings and saved views.
RIGL pages: Overview, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors